6043-00-1

Basic information

• Product Name: 2-Phenyl-3-amino-5-(pyridin-4-yl)pyrazole
• Synonyms: 2-Phenyl-3-amino-5-(pyridin-4-yl)pyrazole
• CAS NO: 6043-00-1
• Molecular Formula: C₁₄H₁₂N₄
• Molecular Weight: 236.27188
• Mol File: 6043-00-1.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Phenyl-3-amino-5-(pyridin-4-yl)pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Phenyl-3-amino-5-(pyridin-4-yl)pyrazole(6043-00-1)
• EPA Substance Registry System: 2-Phenyl-3-amino-5-(pyridin-4-yl)pyrazole(6043-00-1)

Safety Data

• Hazardous Substances Data: 6043-00-1(Hazardous Substances Data)

Upstream product

• 2459-09-8 4-pyridinecarboxylic acid, methyl ester 
• 23821-37-6 3-oxo-3-(pyridin-4-yl)propanenitrile 
• 100-63-0 phenylhydrazine 

Relevant articles and documents

TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention is directed to benzyl urea compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.

TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention is directed to benzyl urea compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.

N-(MONOCYCLIC ARYL),N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.